Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313890721> ?p ?o ?g. }
- W4313890721 endingPage "390" @default.
- W4313890721 startingPage "390" @default.
- W4313890721 abstract "Alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) are widely used as tumor markers to diagnose hepatocellular carcinoma (HCC). Some advanced HCCs demonstrate neither AFP nor DCP. This study investigated the characteristics and prognosis of AFP (<20 ng/mL) and DCP (<40 mAU/ml) double-negative HCC (DNHC) in higher-stage HCC. Between April 2012 and March 2022, 419 consecutive patients were enrolled with newly diagnosed HCC and 372 patients were selected that were diagnosed by histopathology and/or imaging. AFP-negative, DCP-negative, and double-negative HCC were identified in 262 patients (70.4%), 143 patients (38.2%), and 120 patients (32.3%), respectively. In higher-BCLC stages (BCLC-B, C, and D), 17 patients (14.7%) were DNHC. Although there was no difference in BCLC staging, there were more cases under TNM Stage III in DNHC (71.0% vs. 41.4%, p = 0.026). The median maximum tumor diameter was smaller in DNHC [3.2 (1.8−5.0) vs. 5.5 (3.5−9.0) cm, p = 0.001] and their median survival time was significantly better, even in higher-stage HCC [47.0 (24.0−84.0) vs. 19.0 (14.0−30.0) months, p = 0.027). DNHC in higher-BCLC stage HCC is independent of BCLC staging, characterized by a tumor diameter < 5 cm, and is treatable with a good prognosis." @default.
- W4313890721 created "2023-01-10" @default.
- W4313890721 creator A5013892185 @default.
- W4313890721 creator A5015651545 @default.
- W4313890721 creator A5019069199 @default.
- W4313890721 creator A5019106273 @default.
- W4313890721 creator A5028056925 @default.
- W4313890721 creator A5028792183 @default.
- W4313890721 creator A5043762491 @default.
- W4313890721 creator A5047562628 @default.
- W4313890721 creator A5048748793 @default.
- W4313890721 creator A5054696931 @default.
- W4313890721 creator A5057458831 @default.
- W4313890721 creator A5067980352 @default.
- W4313890721 creator A5082951551 @default.
- W4313890721 date "2023-01-06" @default.
- W4313890721 modified "2023-09-30" @default.
- W4313890721 title "The Characteristics and Prognosis of Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin Double-Negative Hepatocellular Carcinoma at Baseline in Higher BCLC Stages" @default.
- W4313890721 cites W1534957296 @default.
- W4313890721 cites W1536289748 @default.
- W4313890721 cites W1755620415 @default.
- W4313890721 cites W1828082159 @default.
- W4313890721 cites W1966429824 @default.
- W4313890721 cites W1971837077 @default.
- W4313890721 cites W1972016167 @default.
- W4313890721 cites W1974402264 @default.
- W4313890721 cites W1979331424 @default.
- W4313890721 cites W1989145315 @default.
- W4313890721 cites W1989711166 @default.
- W4313890721 cites W1990835252 @default.
- W4313890721 cites W2000971652 @default.
- W4313890721 cites W2011062674 @default.
- W4313890721 cites W2012871544 @default.
- W4313890721 cites W2015035889 @default.
- W4313890721 cites W2032976303 @default.
- W4313890721 cites W2036202644 @default.
- W4313890721 cites W2039892671 @default.
- W4313890721 cites W2049916365 @default.
- W4313890721 cites W2055499437 @default.
- W4313890721 cites W2056746886 @default.
- W4313890721 cites W2056774453 @default.
- W4313890721 cites W2064173924 @default.
- W4313890721 cites W2072167444 @default.
- W4313890721 cites W2076327477 @default.
- W4313890721 cites W2080712621 @default.
- W4313890721 cites W2087238991 @default.
- W4313890721 cites W2096066755 @default.
- W4313890721 cites W2117830875 @default.
- W4313890721 cites W2170529511 @default.
- W4313890721 cites W2179141452 @default.
- W4313890721 cites W2277004004 @default.
- W4313890721 cites W2330134488 @default.
- W4313890721 cites W2346764222 @default.
- W4313890721 cites W23602240 @default.
- W4313890721 cites W2417275915 @default.
- W4313890721 cites W2625856057 @default.
- W4313890721 cites W2739498545 @default.
- W4313890721 cites W2786099441 @default.
- W4313890721 cites W2796067155 @default.
- W4313890721 cites W2908573150 @default.
- W4313890721 cites W3006520120 @default.
- W4313890721 cites W3008402334 @default.
- W4313890721 cites W3025581273 @default.
- W4313890721 cites W3027445797 @default.
- W4313890721 cites W3034594171 @default.
- W4313890721 cites W3128646645 @default.
- W4313890721 cites W3177312516 @default.
- W4313890721 cites W3211083932 @default.
- W4313890721 cites W3213277274 @default.
- W4313890721 cites W33875878 @default.
- W4313890721 cites W41633212 @default.
- W4313890721 cites W4249522930 @default.
- W4313890721 cites W4324262569 @default.
- W4313890721 cites W47179371 @default.
- W4313890721 cites W618904051 @default.
- W4313890721 doi "https://doi.org/10.3390/cancers15020390" @default.
- W4313890721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36672339" @default.
- W4313890721 hasPublicationYear "2023" @default.
- W4313890721 type Work @default.
- W4313890721 citedByCount "0" @default.
- W4313890721 crossrefType "journal-article" @default.
- W4313890721 hasAuthorship W4313890721A5013892185 @default.
- W4313890721 hasAuthorship W4313890721A5015651545 @default.
- W4313890721 hasAuthorship W4313890721A5019069199 @default.
- W4313890721 hasAuthorship W4313890721A5019106273 @default.
- W4313890721 hasAuthorship W4313890721A5028056925 @default.
- W4313890721 hasAuthorship W4313890721A5028792183 @default.
- W4313890721 hasAuthorship W4313890721A5043762491 @default.
- W4313890721 hasAuthorship W4313890721A5047562628 @default.
- W4313890721 hasAuthorship W4313890721A5048748793 @default.
- W4313890721 hasAuthorship W4313890721A5054696931 @default.
- W4313890721 hasAuthorship W4313890721A5057458831 @default.
- W4313890721 hasAuthorship W4313890721A5067980352 @default.
- W4313890721 hasAuthorship W4313890721A5082951551 @default.
- W4313890721 hasBestOaLocation W43138907211 @default.
- W4313890721 hasConcept C126322002 @default.
- W4313890721 hasConcept C142724271 @default.
- W4313890721 hasConcept C146357865 @default.